Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nano Dimension Ltd - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Nano Dimension Ltd - ADR trades at $1.48 (market cap $314.71M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 126.8× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NNDM | |
|---|---|---|
Market Cap | $39.89B | $314.71M |
Sector | Health | Technology |
52-Week High | $491.22 | $2.14 |
52-Week Low | $278.09 | $1.21 |
Enterprise Value | $38.15B | -$94.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nano Dimension (NNDM) trades at $1.50, showing no daily change. The technical signal is mixed with a bullish overall signal but bearish moving averages. Fundamentally, the company reported revenue growth to $102.44M in 2025, but net losses deepened to -$293.30M, with a negative net income margin of -286.72%. Recent news highlights boardroom disputes with shareholder Murchinson and a proposed business combination with Infinite Epigenetics.
The outlook remains challenging due to persistent losses and negative cash flow, though the low P/B ratio of 0.65 may attract value investors. Key risks include execution of strategic plans, shareholder activism, and achieving profitability. Analyst sentiment is cautious given the financial performance and corporate governance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
